Studies sleep breathing problems in people with high blood pressure

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with high blood pressure who see their primary care doctor at a taking part centre. It studies sleep breathing problems and blood pressure control.

Age

18 Years and older

Sex

All sexes can join.

Disease stage

Arterial hypertension (high blood pressure).

Earlier treatment

People with active CPAP treatment cannot join.

Main reasons for not taking part

• Cannot complete questionnaires because of physical or mental limits
• Very limiting chronic disease
• Earlier diagnosis of sleep apnoea (OSA) or another sleep disorder
• Active CPAP treatment
• Fixed night shift work

The registry criteria, word for word

What the trial wants to find out

Hypertension is a frequent condition affecting 11M Spanish citizens and is the leading modifiable contributor to cardiovascular disease and death. Our society has already identified balanced diet, physical activity and emotional wellbeing as the 3 pillars of healthy living. Healthy sleep should be incorporated as the fourth pillar, as clearly supported by the extensively available scientific evidence. Targeting sleep is considered the new frontier in cardiovascular prevention. In fact, recent scientific evidence encourages consideration of including sleep disturbances in the top 10 potentially modifiable cardiovascular risk factors. Sleep-disordered breathing affect 30-80% of patients with hypertension. The personalized management of hypertension is challenging due to; i) the misclassification of hypertensive patients (affecting 1 out of 3 patients); ii) the lack of adequate treatment of high mortality risk hypertensive phenotypes today is an unmet clinical need; iii) unawareness of the impact of sleep-disordered breathing as a modifiable risk factor for hypertension. Importantly, the investigators already made the seminal observations showing that the treatment for sleep-disordered breathing reduces blood pressure in the hypertensive phenotypes with the highest mortality risk. Given the need for novel strategies to treat hypertension and, supported by our data, the investigators propose to study and treat sleep-disordered breathing to improve hypertension control. METASLEEP will go beyond current state-of the-art providing a new paradigm for the accurate hypertension classification and treatment. This project will open up a new avenue on the therapeutic potential of the management of sleep-disordered breathing in hypertension.

The 2 groups in the trial

• Patients with nocturnal hypertension and/or non-dipper pattern and diagnosed with OSA

  Patients with nocturnal hypertension and/or non-dipper pattern who undergo a sleep test, obtaining the diagnosis of obstructive sleep apnea, will be treated following the clinical practice standards.

  Treatment: CPAP or usual practice and Monitoring and intervention in follow-up

• Patients with nocturnal hypertension and/or non-dipper pattern and without OSA

  Patients with nocturnal hypertension and/or non-dipper pattern undergoing a sleep test, the result of which is negative for obstructive sleep apnea disease.

  Treatment: Monitoring and intervention in follow-up